Therapeutic uses of urolithins
View Patent ↗The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.
1. A method of treating a solid tumor in a human, said method comprising:
administering to a human in need thereof an effective amount of a urolithin selected from the group consisting of urolithin B, urolithin A, and methyl-urolithin A, wherein the solid tumor is selected from prostate cancer, pancreatic cancer and colon cancer.
2. The method of claim 1 , wherein said solid tumor is prostate cancer.
3. The method of claim 1 , wherein said solid tumor is pancreatic cancer.
4. The method of claim 1 , wherein said solid tumor is colon cancer.
5. The method of claim 1 , wherein said urolithin is urolithin B.
6. The method of claim 1 , wherein said urolithin is urolithin A.
7. The method of claim 1 , wherein said urolithin is methyl-urolithin A.
8. The method of claim 1 , wherein said solid tumor is prostate cancer; and said urolithin is urolithin B.
9. The method of claim 1 , wherein said solid tumor is pancreatic cancer; and said urolithin is urolithin B.
10. The method of claim 1 , wherein said solid tumor is colon cancer; and said urolithin is urolithin B.
11. The method of claim 1 , wherein said solid tumor is prostate cancer; and said urolithin is urolithin A.
12. The method of claim 1 , wherein said solid tumor is pancreatic cancer; and said urolithin is urolithin A.
13. The method of claim 1 , wherein said solid tumor is colon cancer; and said urolithin is urolithin A.
14. The method of claim 1 , wherein said solid tumor is prostate cancer; and said urolithin is methyl-urolithin A.
15. The method of claim 1 , wherein said solid tumor is pancreatic cancer; and said urolithin is methyl-urolithin A.
16. The method of claim 1 , wherein said solid tumor is colon cancer; and said urolithin is methyl-urolithin A.